Related Experiment Videos
Myristic acid-modified thymopentin for enhanced plasma stability and immune-modulating activity
Yuanyan Tan1, Wei Wang2, Chunlei Wu2
1Guangdong Key Laboratory of Nanomedicine, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.
International Immunopharmacology
|April 3, 2017
Summary
Fatty acid conjugation extends the effectiveness of thymopentin (TP5) by enhancing albumin binding and stability. This modified peptide (TP5-MA) shows preserved bioactivity and prolonged immune modulation, reducing administration frequency for immunodeficiency treatment.
Area of Science:
- Bioconjugation Chemistry
- Pharmacology
- Immunology
Background:
- Albumin-binding strategies enhance peptide drug delivery and therapeutic effects.
- Thymopentin (TP5) is a peptide with immune-modulating properties but a short half-life.
- Developing strategies to prolong TP5's efficacy is crucial for treating immunodeficiency.
Purpose of the Study:
- To prolong the half-life and immune-modulating effects of thymopentin (TP5).
- To utilize an albumin binding strategy for enhanced peptide drug delivery.
- To develop a stable and effective TP5 derivative for therapeutic applications.
Main Methods:
- Synthesis of myristic acid-modified TP5 (TP5-MA) via conjugation to a permissive site.
- Assessment of albumin binding affinity and plasma stability of TP5-MA.
- Evaluation of TP5-MA bioactivity in RAW264.7 macrophages using TNF-α stimulation.
- In vivo studies in immune-depressed rat models to assess immune modulation and CD4+/CD8+ ratio.
Main Results:
- TP5-MA exhibited significantly improved albumin binding affinity and enhanced stability in human plasma.
- TP5-MA demonstrated well-preserved bioactivities in macrophage assays.
- In vivo studies confirmed prolonged immune-modulating effects of TP5-MA, normalizing the CD4+/CD8+ ratio.
- Reduced administration frequency (twice weekly) was achieved with TP5-MA.
Conclusions:
- The albumin binding strategy effectively enhanced the pharmacokinetic and pharmacodynamic properties of TP5.
- TP5-MA represents a promising therapeutic candidate for immunodeficiency diseases due to its improved stability and efficacy.
- This approach offers a potential method for developing long-acting peptide therapeutics.